STO · XBRANE.ST
Xbrane Biopharma AB (publ)
SEK 13.00-SEK 2.85 (-17.98%)
Xbrane Biopharma AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 35.0% below the high.
Loading market information…
STO · VIVE.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:20 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Vivesto AB’s quoted price sits in the lower half of its reported 52-week range, 72.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vivesto AB’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vivesto AB’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer. For animal health, Vivesto provides Paccal Vet, leveraging its XR-17 encapsulation technology to deliver paclitaxel for canine mastocytoma, and Doxophos Vet, a proprietary doxorubicin formulation used to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) until its name change to Vivesto AB in March 2022.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 0.00-100.0% vs estimate |
| Q2 2023 | Aug 24, 2023 | -SEK 0.05 | SEK 0.00 |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 13.00-SEK 2.85 (-17.98%)
Xbrane Biopharma AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 35.0% below the high.
SEK 12.65-SEK 0.40 (-3.07%)
SciBase Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 76.57% below the high.
SEK 0.52+SEK 0.01 (+1.37%)
Klaria Pharma Holding AB (publ.)’s quoted price sits in the lower half of its reported 52-week range, 60.98% below the high.
SEK 8.00+SEK 0.12 (+1.52%)
Arcoma AB’s quoted price sits in the lower half of its reported 52-week range, 20.4% below the high.
SEK 0.37+SEK 0.05 (+15.94%)
Biovica International AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 39.18% below the high.
SEK 3.83+SEK 0.03 (+0.66%)
Active Biotech AB’s quoted price sits in the lower half of its reported 52-week range, 59.44% below the high.
SEK 0.40-SEK 0.01 (-2.69%)
AcuCort AB’s quoted price sits in the lower half of its reported 52-week range, 58.11% below the high.
SEK 3.67SEK 0.00 (0.0%)
Scandinavian ChemoTech AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 52.71% below the high.
